首页> 外文期刊>Neurology Research International >Nrf2/ARE Signaling Pathway: Key Mediator in Oxidative Stress and Potential Therapeutic Target in ALS
【24h】

Nrf2/ARE Signaling Pathway: Key Mediator in Oxidative Stress and Potential Therapeutic Target in ALS

机译:Nrf2 / ARE信号传导途径:氧化应激和ALS潜在治疗靶点的关键介体

获取原文
       

摘要

Nrf2 (nuclear erythroid 2-related factor 2) is a basic region leucine-zipper transcription factor which binds to the antioxidant response element (ARE) and thereby regulates the expression of a large battery of genes involved in the cellular antioxidant and anti-inflammatory defence as well as mitochondrial protection. As oxidative stress, inflammation and mitochondrial dysfunctions have been identified as important pathomechanisms in amyotrophic lateral sclerosis (ALS), this signaling cascade has gained interest both with respect to ALS pathogenesis and therapy. Nrf2 and Keap1 expressions are reduced in motor neurons in postmortem ALS tissue. Nrf2-activating compounds have shown therapeutic efficacy in the ALS mouse model and other neurodegenerative disease models. Alterations in Nrf2 and Keap1 expression and dysregulation of the Nrf2/ARE signalling program could contribute to the chronic motor neuron degeneration in ALS and other neurodegenerative diseases. Therefore, Nrf2 emerges as a key neuroprotective molecule in neurodegenerative diseases. Our recent studies strongly support that the Nrf2/ARE signalling pathway is an important mediator of neuroprotection and therefore represents a promising target for development of novel therapies against ALS, Parkinson’s disease (PD), Huntington’s disease (HD), and Alzheimer’s disease (AD).
机译:Nrf2(核红系2相关因子2)是亮氨酸拉链的基本区域,与抗氧化反应元件(ARE)结合,从而调节涉及细胞抗氧化和抗炎防御作用的大量基因的表达以及线粒体保护由于氧化应激,炎症和线粒体功能障碍已被确定为肌萎缩性侧索硬化症(ALS)的重要发病机制,因此这种信号级联反应已引起人们对ALS发病机制和治疗的兴趣。 Nrf2和Keap1表达在死后ALS组织的运动神经元中减少。激活Nrf2的化合物已在ALS小鼠模型和其他神经退行性疾病模型中显示出治疗功效。 Nrf2和Keap1表达的改变以及Nrf2 / ARE信号程序的失调可能会导致ALS和其他神经退行性疾病的慢性运动神经元变性。因此,Nrf2成为神经退行性疾病中的关键神经保护分子。我们最近的研究强烈支持Nrf2 / ARE信号通路是神经保护的重要介质,因此代表了开发针对ALS,帕金森氏病(PD),亨廷顿氏病(HD)和阿尔茨海默氏病(AD)的新疗法的有希望的目标。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号